Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

o discuss the third quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619‐6250 (international), participant code 36014873. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: projected change in 2013 cash, cash equivalents, and marketable securities and expected year-end cash, cash equivalents, and marketable securities balance; the potential for, and timing of, the approval of a Contrave Marketing Authorization Application (MAA) in the European Union (EU); the probability of the interim analysi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... De Pfizer Clinical Research Unit (PCRU) heeft ... van Japanse komaf voor medewerking aan klinisch onderzoek. De ... één van twee onderzoekseenheden van Pfizer , een ... door de ontdekking en ontwikkeling van nieuwe medicijnen. Om ... mannen en vrouwen van Japanse komaf – leeftijd 18 ...
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... 30, 2014 The Board of Directors ... last evening expressed support for the "Pharmacists, Patient ... of Pharmacy Practitioners (JCPP).  As a JCPP member, ... two-year period to develop a scalable, viable and ... "Pharmacists are fast becoming one of the ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... April 5, 2011 Danaher Corporation (NYSE: ... been promoted to Senior Vice President and Amir Aghdaei ... and Group Executive of Danaher. In his ... Danaher,s Dental segment, which includes KaVo Group and Sybron ...
... 5, 2011 Practice Fusion, the fastest growing ... $23 million Series B round of financing led ... Management and Glynn Capital Management, as well as ... round brings the company,s total funding to $30 ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2Founders Fund Leads $23 Million Practice Fusion Financing Round 2Founders Fund Leads $23 Million Practice Fusion Financing Round 3Founders Fund Leads $23 Million Practice Fusion Financing Round 4Founders Fund Leads $23 Million Practice Fusion Financing Round 5
(Date:7/31/2014)... NJ (PRWEB) July 31, 2014 A cancer ... of people survive cancer and resume normal lives. This is ... Cancer Society, will affect one in seven American men but ... has a five-year survival rate of nearly 100% and a ... illness but most men diagnosed with the disease do not ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on nine secrets that addicts don’t want others to know. ... an addict from a mile away, and totally understand what’s ... Per Wickstrom . “However, take it from me: spotting ...
(Date:7/31/2014)... In its latest blog post, Best Drug ... family close by during a stay in rehab can make ... successful, is looking at 10 tips to help drug or ... is a lifelong process, and one that former addicts and ... compromise,” commented Best Drug Rehabilitation’s CEO Per Wickstrom . ...
(Date:7/31/2014)... 31, 2014 Thanks to its ... erythritol has long been used as a medium ... and monk fruit. However consistent, dependable sourcing of ... to meet food and beverage manufacturers’ increasing needs ... has launched GMO-free ErysweetTM Erythritol. , “Erysweet ...
(Date:7/31/2014)... Arizona (PRWEB) July 31, 2014 Nuanced ... announce the launch of the Nuanced Medical website ... created for the needs of the Medical Industry. , ... products and services for medical practices to meet continuously ... regulations being the HIPAA Act (Health Insurance Portability and ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Steviva Ingredients Launches Erysweet Erythritol 2Health News:Nuanced Media, HIPAA Certified Agency, Launches Medical Web Design Service Website 2
... drugs , , WEDNESDAY, June 17 (HealthDay News) -- ... invade the nervous system of patients with a blood-borne ... the development of drugs that block these molecules and ... which primarily strikes children and adolescents, the bone marrow ...
... ... has been regularly engaging its healthcare provider customers in discussions about healthcare reform, the ... technology to address short and long-term healthcare objectives. , ... Stamford, CT (Vocus) June 18, 2009 -- ...
... Today the National Multiple Sclerosis Society - Wisconsin ... 2009 Physician Appreciation Award. The recognition commends Dr. Khatri ... and his research to treat it. , , ... honored to receive this recognition," says Dr. Khatri, medical ...
... 17 PRA International, a leading Clinical Research Organization, announces ... Information Association (DIA) meeting June 21 - 25 in San ... Executive Director of Medical Affairs will make a presentation entitled ... , In addition, Dr. Starkey and other PRA medical, ...
... , Redskins Kicker Shaun Suisham,s Foursome Takes First Place , ... 23rd Annual Maryland Golf Classic presented by Capital Carpets & ... kidney disease in the Washington DC area, a region that ... The tournament took place on June 15 at the picturesque ...
... quality improvement and affordable coverage for all Americans , ... Majority Leaders Howard Baker, Tom Daschle and Bob Dole, ... today released a bipartisan, budget-neutral framework for comprehensive health ... health coverage. The Leaders, Project on the State of ...
Cached Medicine News:Health News:Taking Aim at Relapse of Leukemia in Kids 2Health News:IVANS Hit Experts Available To Discuss the Dept. of HHS Recommendation Of “Meaningful Use” and How Potential Tighter Standards Will Impact the Provider Community 2Health News:IVANS Hit Experts Available To Discuss the Dept. of HHS Recommendation Of “Meaningful Use” and How Potential Tighter Standards Will Impact the Provider Community 3Health News:Aurora Physician Recognized for Multiple Sclerosis Care 2Health News:PRA International Experts Present at the 45th Annual DIA Meeting 2Health News:National Kidney Foundation's 23rd Annual Maryland Golf Classic Raises Funds to Fight Kidney Disease 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 3Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 4
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: